Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
104.90
+0.12 (0.11%)
At close: Jul 18, 2025, 4:00 PM
104.96
+0.06 (0.06%)
After-hours: Jul 18, 2025, 5:38 PM EDT

Company Description

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.

The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma.

Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma plc
Verona Pharma logo
CountryUnited Kingdom
Founded2005
IPO DateApr 27, 2017
IndustryBiotechnology
SectorHealthcare
Employees209
CEODavid Zaccardelli

Contact Details

Address:
3 More London Riverside
London, SE1 2RE
United Kingdom
Phone44 20 3283 4200
Websiteveronapharma.com

Stock Details

Ticker SymbolVRNA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001657312
CUSIP Number925050106
ISIN NumberUS9250501064
SIC Code2834

Key Executives

NamePosition
Dr. David S. Zaccardelli Pharm.D.President, Chief Executive Officer and Executive Director
Mark W. HahnChief Financial Officer
Andrew FisherGeneral Counsel
Dr. Kathleen A. Rickard M.D.Chief Medical Officer
Victoria StewartSenior Director of Investor Relations and Communications
Matthew CasbonVice President of Sales, Marketing and Training
Ostra JewellSenior Vice President of Human Resources
Dr. Tara Rheault M.P.H., Ph.D.Chief Development Officer
Christopher MartinChief Commercial Officer
Caroline DiazChief Regulatory Officer

Latest SEC Filings

DateTypeTitle
Jul 10, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 10, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 9, 2025DFAN14AFiling
Jul 9, 2025DFAN14AFiling
Jul 9, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 9, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 9, 20258-KCurrent Report
Jul 9, 2025DFAN14AFiling
Jun 11, 2025144Filing
Jun 11, 2025144Filing